



**SCHEDULE**

▲

AI2V 1: Waltham, MA - 8/1-4  
AI2V 2: Urbana, IL - 9/9-12  
Southfield, MI - 9/28  
Kansas City, MO - 9/29  
St. Paul, MN - 10/6  
 Fargo-Moorehead, MN - 10/12  
Oxnard, CA - 11/2

▼

[About Us](#)

[Events](#)

[Resources](#)

[Archives](#)

[Purchase the I2V Participant Guide](#)

[Read our Weblog](#)

[Contact I2V](#)

MADE POSSIBLE BY:



## ARCHIVES - 2006

### I2V Vermont: Speaker Profiles

Click on a name to learn more about the speaker.

- [John E. Abele](#)
- [Mark Blanchard](#)
- [Frances Carr](#)
- [Cairn Cross](#)
- [John Evans](#)
- [Ruth Farrell](#)
- [Robert Foster](#)
- [Richard Galbraith](#)
- [Richard Jenny](#)
- [Todd Keiller](#)
- [Christopher Landry](#)
- [Benjamin Littenberg](#)
- [Helen Lockhart](#)
- [Joseph Lovett](#)
- [Lawrence Meier](#)
- [Ken Merritt](#)
- [Richard Munkelwitz](#)
- [David Potter](#)
- [Thomas Rainey](#)
- [Frank Sadowski](#)
- [Kerry Swift](#)
- [Robert Urban](#)
- [Fred Wainwright](#)
- [Phil Weilerstein](#)

#### John E. Abele

John Abele is the Founder Chairman of Boston Scientific Corporation (BSX on NYSE), a 19,000 employee, \$8 billion world wide company that is a pioneer and leader in the field of "Less Invasive Medicine." John holds numerous patents and has published and lectured extensively on the technology of various medical devices and on the technical, social, economic, and political trends and issues affecting healthcare.

His major interests are science literacy for children, education, and the process by which new technology is invented, developed, and introduced to society. Current activities include chair of the FIRST Foundation which works with high school kids to make being science-literate cool and fun and development of The Kingbridge Centre ([www.kingbridgecentre.com](http://www.kingbridgecentre.com)) and Institute, a conferencing institution whose mission is to research, develop, and teach improved methods for interactive conferencing: problem solving, conflict resolution, strategic planning and new methods for learning.

[Back to top](#)

#### Mark Blanchard, Technology Development & Commercialization Advisor

Mark provides free business counseling to technology-based innovative small businesses statewide for Vermont Small Business Development Center (VtSBDC). Clients range from 100+ employee firms with revenues in excess of \$20 million to start-up ventures. Areas of counseling include seeking R&D funding, especially through SBIR/STTR programs, general business strategy, business planning and raising capital. Prior to consulting for small firms he was Vice President of Synergy Innovations Inc., a technology development firm which won numerous SBIR awards. He served as marketing manager for a small firm producing innovative compacting presses and also owned a restaurant. His corporate experience includes seven years as Vice President, Administration for Thermal Dynamics Corporation preceded by eight years, largely overseas, in management and strategic planning roles with Caltex Petroleum. Mark is a former U.S. Navy engineering officer. He graduated from Dartmouth College and

after the Navy earned his MBA at the Amos Tuck School.

[Back to top](#)

#### **Frances Carr Ph.D., VP Research & Graduate Studies, University of Vermont**

Fran Carr joined the University of Vermont in August 2003. She is responsible for enhancing research and scholarship, developing a comprehensive research plan, expanding the university's technology and innovation and strengthening graduate education. She will also oversee the development and expansion of research partnerships to enhance economic development.

Prior to joining UVM, Carr was the Vice President for Research and Economic Development and Professor of Biological Sciences at Binghamton University at the State University of New York. Carr served on the Board of Directors of the Research Foundation of the State University of New York, the Board of Directors of the Innovative Technologies Corporation, a Binghamton University technology incubator, the Southern Tier Opportunity Coalition, an industry collaboration to enhance innovative technologies among others.

Recognized for more than 20 years of scientific research, teaching and administrative experience, with more than 90 publications and articles, Carr came to Binghamton in 1999 from a post as senior science advisor with the U.S. Agency for International Development (USAID). There her scientific expertise and strengths in policy and strategic planning had earned her a senior-level Presidential appointment in 1993. While serving as a Clinton administration appointee, she authored more than 20 foreign policy documents and strategies. She also served on the National Science & Technology Council as co-chair of the Committee for International Science, Engineering and Technology and as co-chair for the US-EU Committee on Emerging and Re-emerging Infectious Diseases.

Carr received a BS in biology and psychology from Boston College and a PhD in physiology and biophysics from the University of Illinois Medical Center. Her subsequent appointments at the University of Minnesota and Harvard Medical School fostered her research and teaching in endocrinology and molecular biology.

[Back to top](#)

#### **Cairn Cross, Co-founder, FreshTracks Capital and Managing Director of the Fund**

Cairn Cross is a co-founder of FreshTracks Capital and serves as a Managing Director of the Fund. From 1996 to 2000 he owned and operated Cross Vermont Financial, a strategic and financial consultancy to Vermont banks and growth businesses such as Collector Online, Otter Creek Industries, Green Mountain Coffee Roasters, and the Merchants Bank. Cairn served as the CFO of Otter Creek Industries to restructure its operations prior to achieving a profitable sale of the company.

From 1996 to 1998, Cairn was the Assistant General Manager of Green Mountain Capital, L.P. From 1991 to 1996 he was a Vice President and Corporate Loan Officer for the Howard Bank, preceded by five years service in various positions for Vermont National Bank including Commercial Loan Officer. Cairn is an investor in and a Member Manager of Snow Farm Vineyard, LLC, Vermont's first grape wine producer located on Grand Isle.

Cairn serves as Co-Chair and Steering Committee member of the Vermont Investors' Forum, an annual "venture fair" for Vermont companies, and previously served on the board of directors of the Addison County Economic Development Authority. In 2002, he was appointed by Governor Howard Dean to the Vermont State Board of Public Accountancy and to the Workforce Recruitment Board. He was reappointed to the Workforce Recruitment Board by Governor James Douglas in 2005. Also in 2005, Cairn was appointed by Speaker of the Vermont House, Gaye Symington to her business advisory committee.

Cairn earned a B.S. (1981) from Montana State University and an MBA (1987) from New Hampshire College (now Southern New Hampshire University). He lives in Ferrisburg, Vermont.

[Back to top](#)

#### **John N. Evans, PhD, Dean, College of Medicine, University of Vermont**

John N. Evans, Ph.D., was named the 16th Dean of the University of Vermont College of Medicine in January, 2004.

Dr. Evans, who is also a professor of physiology and biophysics, had been serving as Acting Dean since June, 2003, and was previously Senior Advisor to the Dean of the College of Medicine as well as Senior Advisor for Strategic Initiatives to President Daniel Mark Fogel. He served as Executive Dean of the College of Medicine from 1992 to 2001, and was Interim Dean during 2000.

Evans led the efforts that transformed the College of Medicine campus through the construction of the Health Sciences Research Facility and the Medical Education Center. He formalized the technology transfer process for the College, resulting in increased patents and licensing agreements. Along with former Dean John Frymoyer, M.D., Evans also initiated the effort to redesign the medical curriculum that was launched in fall 2003. External funding for research more than tripled over the last decade. As Senior Advisor to the President, Evans played a significant role in the acquisition of the Trinity College campus and led the planning for the Vermont Center for Emerging Technologies, a high technology business incubator.

In 2000, Evans received the Alpha Omega Alpha Honor Society Award, and was also honored with the Founders Award by the Vermont Medical Society in recognition of his outstanding leadership, vision and achievements in improving the health of Vermonters and all Americans.

Evans has published extensively on lung disease and served on the Editorial Board of several journals, including Pulmonary Pharmacology, American Review of Respiratory Diseases, and American Journal of Physiology. He is also a reviewer for the journals Lung, Experimental Lung Research, Journal of Pharmacology and Experimental Therapeutics, and American Journal of Physiology.

Evans has served on the Board of the Vermont Technology Council and currently serves on the Board of the Vermont Center for Emerging Technologies. He is also a member of the Board of Trustees of Fletcher Allen Health Care, the College of Medicine's partner in Vermont's academic health center.

Evans received a doctorate in physiology in 1976 from the University of Florida, joined the faculty at the University of Vermont College of Medicine in 1976, and was appointed full professor in 1990. He has a longstanding interest in basic research related to the lung.

[Back to top](#)

#### **Ruth Farrell, Associate Vice President for Research Administration at UVM**

Ruth Farrell is the Associate Vice President for Research Administration at the University of Vermont, where she previously served as the Director of the Office of Sponsored Programs. Last year marked Ms. Farrell's 20th in research administration. Over her career she has served in many capacities, from coordinating of a variety of special projects aimed at enhancing the effectiveness of administrative support for faculty grant-seekers to serving as lead research administrator in the College of Medicine. She has been a presenter for the National Council of University Research Administrators (NCURA) and currently serves as a member of NCURA's distance learning faculty. Ms. Farrell holds an MBA from the University of Vermont.

[Back to top](#)

#### **Robert G. Foster, General Partner, Masthead Venture Partners**

Over the course of Robert G. Foster's 40-year career, he has founded and served in a variety of senior executive positions in a wide range of life sciences and technology companies. Until recently, Mr. Foster also served as Chairman, President, and Chief Executive Officer of Commonwealth BioVentures, Inc. ("CBI"), a private, seed venture capital company founded in 1987. In 1976, he founded Ventrex Laboratories, Inc., a public corporation involved in the research, development, manufacturing and sale of diagnostic and biotechnology products. He served as its Chairman, President, and Chief Executive Officer until 1987.

From 1964 to 1976 Mr. Foster was at Corning, Inc., where he held numerous positions starting from entry level research through research management, project management, manufacturing, marketing, divisional technical director, and finally Founder and Manager of Corning Biological Products.

Mr. Foster is a founding partner of Masthead Venture Partners. Masthead has six General Partners and currently has a \$150MM Venture Fund primarily focused on IT.

Mr. Foster holds a BS in Mechanical Engineering from Virginia Polytechnic Institute and a MS in Mechanical Engineering from the Massachusetts Institute of Technology.

[Back to top](#)

#### **Richard A. Galbraith, UVM Clinical Research**

Dr. Galbraith brings 30 years of experience in health care, basic and clinical research and research administration. Previously he was the Program Director of the General Clinical Research Center at the Rockefeller University. Since moving to Vermont in 1995, he has been Professor of Medicine, Chief of the Division of Clinical Pharmacology, Program Director of the General Clinical Research Center and Associate Dean for Patient Oriented Research. He has had experience in taking a novel compound through basic laboratory investigations, toxicology, filing for an IND and carrying out Phase I and Phase II clinical research studies. He has also consulted for the pharmaceutical industry with companies such as Glaxo Smith-Kline, Parke Davis and MitoKor. Richard holds an M.D. degree from King's College, London, England and a Ph.D. in Molecular and Cellular Biology and Pathobiology from the Medical University of South Carolina. He is a Fellow of the Royal College of Physicians.

[Back to top](#)

#### **Richard Jenny, Haemtech Technologies**

Dr. Jenny's professional career spans 25 years and encompasses the fields of coagulation research and protein biochemistry. In 1987, Dr. Jenny and four colleagues from the University of Vermont co-founded Haematologic Technologies, Inc. (HTI), located in Essex Junction, VT. Serving as the President and Chief Scientific Officer of HTI, Dr. Jenny has led the company through its growth from a start-up two-person operation to an internationally recognized company specializing in coagulation reagent manufacturing and contract research. During this time, Dr. Jenny has also served on the editorial board of the Biotechnology and Applied Biochemistry journal and as an ad hoc reviewer for Blood and the Biochemical Journal. He is a member of the advisory committee for the Bioscience Technology program at Vermont Technical College (VTC) and mentors intern students enrolled in the VTC program. He is also a member of the NIH Hematology SBIR/STTR Special Emphasis Review Panel. Dr. Jenny holds a B.S. degree in Chemistry from the University of Wisconsin-Eau Claire and a Ph.D. in Biochemistry from the University of Vermont.

[Back to top](#)

**Todd Keiller, Director of Technology Transfer, University of Vermont**

Mr. Keiller brings 32 years of licensing, business development, and marketing experience. He has worked for 16 years in the industrial sector in a variety of sales, marketing, and business development roles, 10 of which were with Corning Glass Works in their Science and Medical Products Divisions. He has over 16 years of academic licensing experience and is the former Vice President, Ventures of the Brigham and Women's Hospital in Boston. In 1998, Todd joined the University of Vermont and assisted the College of Medicine in technology affairs. In 1999, he was appointed Director of Technology Transfer for the entire University. He also handles the technology transfer for Maine Medical Center, Caritas St. Elizabeth's Medical Center of Boston, and Boston Biomedical Research Institute. Todd has contributed to the founding 7 companies with the most recent being Nephromics, a company focused on the diagnosis of precalmpasia, Vascular Genetics, Inc., a gene therapy company, now traded publicly under the name of CorAutus, and Tolerance Pharmaceuticals, a diagnostic and therapeutic company devoted to transplantation which was purchased by Roche. Todd holds an AB from Dartmouth College and an MBA from the Tuck School of Business Administration.

[Back to top](#)

**Christopher Landry, Associate Professor, UVM**

Chris Landry graduated from the University of Richmond in 1990, and then completed his Ph.D. in Chemistry at Harvard University in 1994. After working at the University of California at Santa Barbara, he joined the UVM's Department of Chemistry in 1996. He recently founded Apollo SRI, in 2002, to commercialize technology developed at UVM. Apollo SRI was one of the first three companies involved in the Vermont Center for Emerging Technologies.

[Back to top](#)

**Benjamin Littenberg, MD, Director of General Internal Medicine and the Program for Research in Medical Outcomes**

Dr. Littenberg is the Henry and Carleen Tufo Professor of Medicine and Professor of Nursing at the University of Vermont where he is also Director of General Internal Medicine and the Program for Research in Medical Outcomes. He received his medical degree from Case Western Reserve University and trained in internal medicine at Hartford (Connecticut) Hospital. He was a Robert Wood Johnson Clinical Scholar at Stanford University before becoming Assistant Professor of Medicine at Dartmouth. Following an appointment as Associate Professor of Medicine at Washington University in St. Louis, he assumed his present position in 1999.

Dr. Littenberg's research interests center on technology assessment and quality improvement. Recent projects include new ways to measure quality of care in cancer, novel strategies for reporting test results to patients, better approaches to antibiotics in sinusitis, safety improvements in outpatient prescriptions, and strategies to address health literacy. In Vermont, Dr. Littenberg has been active on the Board of the Vermont Program for Quality in Health Care. He has developed statewide registry-based approaches to quality and safety improvement with the Vermont Breast Cancer Surveillance System and as Principal Investigator of the Vermont Diabetes Information System. He is Chief Executive Officer of Vermont Clinical Decision Support, LLC, which was organized to distribute the Vermont Diabetes Information System and other tools to improve care.

Dr. Landry received his Ph.D. in 1994 from Harvard University, where he worked with Professor Andrew Barron. He did his postdoctoral research with Professor Galen Stucky at the University of California at Santa Barbara and joined the faculty in 1996.

[Back to top](#)

**Helen Lockhart, Senior Patent Attorney at Wolf, Greenfield & Sacks**

Helen Lockhart is the Chair of the firm's Biotechnology Practice Group. Her practice involves securing and enforcing domestic and international intellectual property rights. She counsels a variety of clients, including universities, smaller and mid-sized companies, start-ups and entrepreneurs.

Helen has broad experience in prosecuting biotechnology patents relating to human gene therapy, improved immune response modulators, drug delivery, catalytic molecules, antibodies, fluorescence based micro- and nano-analysis, cell culture, mass spectrometry, nucleic acid sequencing, polymer-based and biological-based drug delivery systems, antisense nucleic acid therapeutics, newly discovered genes for diagnostic and therapeutic uses, peptides, small molecule mimetics, combinatorial libraries and drug screening assays.

Her doctoral research focused on the regulation of cellular growth and differentiation through signal transduction mechanisms.

Helen is admitted to Massachusetts Bar and is registered to practice before the U.S. Patent and Trademark Office. She is also a member of the American Bar Association, Massachusetts Bar Association, Boston Patent Law Association, and Boston Bar Association. Helen has been named in Boston Magazine as one of Massachusetts' "Super Lawyers" in the field of intellectual property.

[Back to top](#)

**Joseph F. Lovett, Managing Director of The Louisiana Fund**

Joseph F. Lovett, is the Managing Director of The Louisiana Fund, a new early stage venture fund located in Baton Rouge, LA. Mr. Lovett has over 34 years of venture capital and operations experience in healthcare areas of biotechnology, medical devices, and equipment, diagnostics, imaging and services. Operations experience included increasingly responsible positions in marketing and general management at CR Bard, Mallinckrodt, and Damon Biotech. Venture capital experience includes three venture capital funds (1988-present) as general partner in affiliation with Harvard University managing \$70,000,000 which resulted in 13 IPOs, 5 sales of private companies, 6 private companies (1 in IPO registration) and 7 write offs. Mr. Lovett has a BA in economics from the University of Vermont, and a MBA from California State Polytechnic University.

[Back to top](#)

#### **Lawrence H. Meier is a director in the law firm Downs Rachlin Martin PLLC**

Lawrence H. Meier is a director in the law firm Downs Rachlin Martin PLLC, where he chairs the Intellectual Property Practice Group. Larry is a registered patent attorney with the U.S. Patent and Trademark Office, and represents a wide range of clients, from start-ups to Fortune 100 companies, in connection with copyright, patent, trademark and trade secret matters. He handles a wide range of intellectual property (IP) transactions, has more than 20 years of patent prosecution experience in the electrical, computer and mechanical arts, and assists clients with all aspects of trademark clearance and protection. He also represents clients in IP litigation in state and federal courts, in the U.S. Patent and Trademark Office and in arbitration and mediation proceedings. Before joining DRM, Larry was a Senior Intellectual Property Attorney with the IBM Corporation. He holds a bachelor's degree from Miami University, and earned his law degree from Vermont Law School, where he now teaches as an adjunct professor.

[Back to top](#)

#### **Ken Merritt, Managing Director of Merritt & Merritt & Moulton**

Ken Merritt is the Managing Director of Merritt & Merritt & Moulton, a law firm with offices in Burlington, Vermont and W. Lebanon, New Hampshire, focusing on the representation of emerging growth companies throughout the Northeast. The firm provides strategic counsel for financial, intellectual and organizational capital to clients in a variety of business sectors. The firm's clients range from early-stage enterprises to NASDAQ-listed companies. In addition, the firm represents individual and institutional investors in venture capital transactions. Mr. Merritt began his career in New York City focusing on debt and equity financing and mergers and acquisitions and has over 26 years of experience representing emerging growth companies and institutional and individual investors.

Mr. Merritt is the founder and President of the Vermont Venture Network and a director and Co-Chair of the Vermont Investors' Forum, Inc. He is an active angel investor and is a member of North Country Angels. He formerly served as a director and Secretary of Vermont Businesses for Social Responsibility and is currently a member of the Nominating Committee. Mr. Merritt is a graduate of the University of Michigan and the Columbia University School of Law.

[Back to top](#)

#### **Richard Munkelwitz, Program Manager for the Vermont Center for Emerging Technologies (VCET)**

Mr. Munkelwitz is Program Manager for the Vermont Center for Emerging Technologies (VCET), an affiliate of the University of Vermont. He has spent his career working with emerging and mature technology companies in information services, telecommunications, healthcare, medical devices, the biosciences and the environmental sciences. He has held senior positions at Amoco Corporation, First Chicago Corporation and the Sanwa Bank Ltd; he co-founded Crossroads Ventures, a Vermont headquartered mergers and acquisitions firm. In addition to many transactions in arranging venture capital, equity and debt financing, he has served as advisor, board member or member of management for emerging technology companies. In his role as program manager for VCET, Richard helps member companies achieve their business objectives and provide job growth for the State of Vermont. He is a graduate of the Massachusetts Institute of Technology and Columbia University.

[Back to top](#)

#### **David L. Potter, Founding Principal & Consultant numerous early stage life sciences companies**

David L. Potter has been a Founding Principal in, and consultant to, numerous early stage and expansion stage life sciences, consumer products, and business services companies. Dave's company, Momentum Ventures Associates LLC, specializes in bringing in-depth entrepreneurial business acumen to companies with promising intellectual property, but limited business-building and management resources.

In 1997, Dave co-founded Pro-Change Behavior Systems, Inc., a spin-off company from the University of Rhode Island. Pro-Change became a leader in delivering health care compliance solutions for obese and smoking populations. From 2000 until the company's sale in 2002, he served as Chief Operating Officer of Previser Health Solutions, Inc., a start-up company with licensed technology from the University of Washington and the Temple University Medical School. Previser's technology is currently serving chronic disease patients in Israel and the United Kingdom, as well as in the United States.

Dave has subsequently served as a strategic guide and hands-on operating mentor to nine New England companies, ranging from start-ups to a division of a Fortune 200 health care company. He is currently providing consulting help to Vermont Clinical Decision Support, LLC, which licenses its core technology from the University of Vermont.

During his corporate career, Dave served in senior Marketing and General Management positions for divisions of Textron Inc., General Mills, Inc. and the Unum Corporation. He was a senior member of the New Ventures organizations at both General Mills and Unum, driving the commercialization of new product and marketplace expansion initiatives.

Dave received his undergraduate degree from Bowdoin College, and his Masters Degree in Business Administration from Dartmouth College. He is a member of the Association for Corporate Growth, the Keiretsu Forum, the National Association of Corporate Directors, and the MIT and Brown University Venture Forums.

[Back to top](#)

#### **Thomas Rainey, President of the Vermont Center for Emerging Technologies (VCET) in Burlington, Vermont**

Thomas Rainey is the President of the Vermont Center for Emerging Technologies (VCET) in Burlington, Vermont. VCET is a targeted, high-technology business incubator program affiliated with the University of Vermont.

Prior to his current position, Mr. Rainey served as a principal consultant with Rainey & Associates providing technology-based economic development solutions to clients including Dartmouth College; University of New Hampshire, the State of New Hampshire; the State of Wisconsin; University of Wisconsin, the State of Vermont, Vermont Technology Council and others.

Mr. Rainey served as the Director of NASA/Kennedy Space Center's technology incubator programs from 1998 through 2000 and was the Director of the St. Louis Enterprise Centers, St. Louis, Missouri from 1993 through 1998. From 1989 through 1992 Mr. Rainey served as Director of the California Central Coast World Trade Center in Ventura County, California.

Tom holds a Master's Degree in Science and Technology Policy from Lund University, Sweden; a Graduate Degree in Social Sciences from the University of Stockholm, Sweden, and a Bachelor of Science in Political Science from Washington University, St. Louis, Missouri.

[Back to top](#)

#### **Frank H. Sadowski, SPHR, Partner, Gallagher, Flynn & Company, LLP**

In 1997, Frank Sadowski joined GFC and established the Human Resources Consulting Division. This group is now the largest human resources consulting business and the largest executive recruiting practice in Vermont. He was made a partner of the Firm in 2003. In addition to continuing to build the Firm's practice in this area, Frank's work with clients focuses in the areas of Compensation, Recruiting, and Organizational Development.

Immediately prior to coming to GFC, Frank was the Principal of Sadowski Consulting Services in South Burlington, Vermont for seven years. Before that, he was Human Resource Manager for Boise Cascade's paper mill in Sheldon Springs, Vermont; Assistant to the President of the University of Vermont; and Chief of Economic Development Planning in the Vermont State Government.

Frank received his undergraduate degree in psychology from Cornell University, attended Harvard Divinity School as a Rockefeller Fellow, and earned a Master's in Public Policy from the University of Michigan. He has received Senior Professional Human Resources (SPHR) certification, the highest level available, from the Society of Human Resources Management. Outside the firm, Frank helped create Burlington's Ronald McDonald House and the Lake Champlain Waldorf School. He has served as a trustee of the Pine Ridge School and president of the Vermont Chapter of the American Society for Training and Development.

[Back to top](#)

#### **Kerry Swift, Technology Transfer initiatives at the University of Vermont**

Kerry Swift assists in the management of technology transfer initiatives at the University of Vermont and supports the Office of Sponsored Programs with industry related research activities. Kerry joined the UVM office in 2004 after 6 years at the Technology Licensing Office at MIT. Kerry holds a MS in Molecular Biology from Tufts University and is a biochemistry graduate of the University of New Hampshire.

[Back to top](#)

#### **Robert G. Urban, PhD., President and CEO, Acretia Inc.**

Dr. Urban has an established track record in drug development and business affairs. Prior to founding Acretia a translational drug development company focus on Oncology and immunology related diseases, Dr. Urban was co-founder of ZYCOS Inc. where he served in several executive functions from VP of New Technology to overseeing Corporate Development, Operations and Clinical Affairs. ZYCOS was formed from Pangaea Pharmaceuticals, Inc.. At Pangaea, Dr. Urban oversaw the Company's Infectious Disease and Oncology drug development programs. These efforts put several proprietary compounds into successful clinical trials. ZYCOS was acquired by the multi-billion dollar specialty

oncology company MGI Pharma (MOGN). The resulting company MGI Pharma Biologics is actively pursuing the registration trials of ZYCOS' oncology and anti-viral products. Dr. Urban is a recognized expert in drug development and a frequent speaker at international conferences. Prior to his executive career, Dr. Urban studied Structural Immunology at Harvard College where he was an Irvington Institute Fellow. Dr. Urban received a doctoral degree from the Department of Microbiology and Immunology at The University of Texas Medical Branch where he received the James W. McLaughlin Award for Research Excellence in Infection and Immunity.

[Back to top](#)

**Fred Wainwright, Executive Director, Private Equity and Entrepreneurship, Tuck School of Business at Dartmouth**

Fred Wainwright is the Executive Director of the Center for Private Equity and Entrepreneurship at the Tuck School of Business at Dartmouth. Fred is also Adjunct Associate Professor at Tuck and teaches MBA and executive education courses in private equity, finance, and entrepreneurship. He is a member of the Board of Advisors of North Atlantic Capital, a late stage venture capital firm, and is Executive Director of North Country Angels and Granite State Angels. Fred is an investor and board member in growth companies. Fred has authored and co-authored numerous reports, cases, articles, and a book on various finance, entrepreneurship, and strategy topics. He also serves on the editorial board of the Journal of Entrepreneurial Finance and Business Ventures. He earned his BA in Economics and BS in Engineering from Stanford University and his MBA from the Tuck School of Business.

[Back to top](#)

**Philip J. Weilerstein, Executive Director, NCIIA**

Philip J. Weilerstein is executive director of the NCIIA. He attended the University of Massachusetts Amherst where, as a graduate student, he co-founded EcoScience Corporation, a publicly held bio-technology company. In addition to his role with the NCIIA, Weilerstein consults for a variety of start-up firms in the areas of strategic planning and quality management.

[Back to top](#)

[Back to workshop](#)

---

NCIIA • 100 Venture Way, Hadley MA 01035 • Tel: 1.413.587.2172 • Fax: 1.413.587.2175 • [www.nciia.org](http://www.nciia.org) •  
[info@invention2venture.org](mailto:info@invention2venture.org)  
© 2005 NCIIA All Rights Reserved.